BACKGROUND: Comorbidity and socioeconomic status (SES) may be related among cancer patients. METHOD: Population-based cancer registry study among 72 153 patients diagnosed during 1997 -2006. RESULTS: Low SES patients had 50% higher risk of serious comorbidity than those with high SES. Prevalence was increased for each cancer site. Low SES cancer patients had significantly higher risk of also having cardiovascular disease, chronic obstructive pulmonary diseases, diabetes mellitus, cerebrovascular disease, tuberculosis, dementia, and gastrointestinal disease. One-year survival was significantly worse in lowest vs highest SES, partly explained by comorbidity. CONCLUSION: This illustrates the enormous heterogeneity of cancer patients and stresses the need for optimal treatment of cancer patients with a variety of concomitant chronic conditions.
People of a lower socioeconomic status (SES) generally have poorer health status and higher mortality than people of higher SES (Jemal et al, 2008; Mackenbach et al, 2008) , also with respect to cancer, with in general higher incidence rate of all cancers combined among people from lower socioeconomic groups (Dalton et al, 2008) . A differential distribution of known risk factors for specific neoplasms between SES groups seems a likely explanation for the above inequalities. For example, the prevalence of smokers has become higher among lower classes (Lahelma et al, 1997; Stronks et al, 1997) , probably resulting in higher rates of cancer of the lung, larynx, mouth, pharynx, oesophagus, and bladder (Siemiatycki et al, 1995; Stellman and Resnicow, 1997; Tyczynski et al, 2003) . However, smoking is not only related to cancer but also to chronic obstructive pulmonary diseases (COPD) and cardiovascular diseases (Doll et al, 1994) . Hence, the high prevalence of comorbidity among lung cancer patients (Janssen-Heijnen et al, 1998) . Socioeconomic status may thus be associated with comorbidity among cancer patients. Thus, medical doctors are presented with a heterogeneous group of cancer patients, for whom appropriate individual treatment must be chosen, taking concomitant conditions into account (Ayanian et al, 2003; Lash et al, 2003; Janssen-Heijnen et al, 2004; Lemmens et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005) .
We studied in a large population-based group of cancer patients the prevalence of comorbidity according to SES, not only by number of concomitant diseases, but also for specific diseases that affect patients with the various tumour sites.
MATERIALS AND METHODS
The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the south of the Netherlands (2.4 million inhabitants, 15% of the Dutch population); it also records serious comorbidity according to an adaptated list (Charlson et al, 1987) . Chronic obstructive pulmonary diseases, cardio-and cerebrovascular diseases, peripheral arterial disease, other malignancies, and diabetes mellitus, connective tissue diseases, rheumatoid arthritis, kidney, bowel, and liver diseases, dementia, tuberculosis and other chronic infections were also recorded. For most analyses peripheral arterial disease was included in the cardiovascular diseases, although gastrointestinal diseases were grouped (gastric diseases, Crohn's disease, ulcerative colitis, liver cirrhosis, and hepatitis). Comorbidity was defined as life-shortening disease that was present at the time of cancer diagnosis and/or received treatment or surveillance. Trained registry personnel actively collect data on diagnosis, staging, and treatment from the medical records after notification by pathologists and medical registration offices. Previous admissions, letters from and to general practitioners and other specialists, the medical history and preoperative screening were used as sources.
Patients with cancer of the oesophagus, stomach, colon or rectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, bladder, kidney, and non-Hodgkin's lymphoma (NHL), newly diagnosed between 1997 and 2006 (n ¼ 72 153), were included in this study; cancers diagnosed at autopsy (n ¼ 369) were excluded.
Statistics Netherlands developed an indicator of SES, using individual fiscal data on the economic value of the home and household income, and is provided at aggregated level for each postal code (covering an average of 17 households). Socioeconomic status was categorised as low (deciles 1 -3), medium (deciles 4 -7), or high social class (deciles 8 -10), and a separate class for postal codes for a long-term care providing institution (such as a nursing home; van Duijn and Keij, 2002) . We calculated the distribution of cancer patients across socioeconomic strata according to tumour localisation, also by gender and age. Patients for whom the SES was unknown (n ¼ 766, 1%) or for whom the postal code included a care providing institution (n ¼ 3569, 5%), as well as those with unknown comorbidity (n ¼ 8399, 12%) were excluded from the analyses of SES and comorbidity. Differences in distribution were tested with the w 2 test. Logistic regression analyses of the odds of having a specific concomitant disease were performed age-and gender-adjusted for all tumour sites combined, and according to tumour site for four concomitant diseases separately; cardiovascular disease, COPD, diabetes mellitus, and gastrointestinal disease. Statistical significance of an overall effect of SES on the prevalence of a specific condition was tested using the w 2 -likelihood ratio test. Crude 1-year survival rates were calculated for all studied tumours combined and for the most important tumour sites separately. Cox's regression models were used to compute multivariate rates (hazard ratio ¼ HR) and 95% confidence intervals (95% CI). The relative contribution (%) of adding comorbidity to the model was calculated as follows: ((HR model AÀHR model B)/(HR model AÀ1)) Â 100, where A is the basic model (age-and genderadjusted) and in model B comorbidity is added to model A. All statistical analyses were performed using SAS V9.12 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Male cancer patients were older than female patients (Table 1) , the median age being 69 and 64 years, respectively (Po0.0001). At the time of the diagnosis of the cancer 71% of male and 58% of female cancer patients had at least one concomitant disease. The most frequent concomitant condition for males with cancer was cardiovascular disease (23%), for women hypertension (20%), among cancer patients older than 70 the prevalence of these diseases was 34% and 31%, respectively. In the subgroup of cancer patients with two or more concomitant diseases, the most frequent combination of diseases among males was cardiovascular disease with hypertension (14%) and in females diabetes with hypertension (21%).
The proportion of patients by SES varied for the different tumour sites (Table 2) . Patients under age 70 with stomach, lung, bladder, or cervical cancer more often had low SES. High SES was more frequent among patients with melanoma or breast, colorectal, or prostate cancer in this age group.
Among patients aged 70 þ with cancer of the oesophagus, stomach, or lung, low SES was clearly over-represented. High SES was more frequent among patients with prostate cancer or NHL.
For all tumour localisations the proportion of patients without comorbidity was highest in the high SES group (Figure 1 ). A gradient towards more concomitant conditions appeared in lower SES groups (Po0.001), which had a significantly higher risk of cardiovascular disease (OR low vs high SES ¼ 1.4, 95% CI: 1.3 -1.5), COPD (OR ¼ 1.8 (1.7 -1.9)), diabetes mellitus (OR ¼ 1.5
(1.4 -1.6)), cerebrovascular disease (OR ¼ 1.5 (1.4 -1.7)), tuberculosis (OR ¼ 1.3 (1.1 -1.6)), dementia (OR ¼ 1.3 (1.0 -1.8)), gastrointestinal disease (OR ¼ 1.5 (1.4 -1.6)), and two or more concomitant conditions (OR ¼ 1.8 (1.7 -1.9)) in addition to their (Table 3 ). The risk of having cancer and also at least one other serious concomitant disease was 50% higher in the low SES than in the high SES group (OR ¼ 1.5 (1.4 -1.6)).
For four concomitant conditions we stratified by tumour localisation (Figure 2 ). The risk of cardiovascular disease among low compared with high SES patients was significantly higher (1.4 -1.6 times) for patients with stomach, colorectal, lung, breast, prostate, and bladder cancer. The risk of COPD was elevated among low SES patients with cancer of the stomach, colorectum, pancreas, lung, breast, corpus uteri, prostate, and kidney (OR's ranging from 1.4 to 2.2). The risk of diabetes mellitus was highest among people from low SES with breast cancer (OR ¼ 2.0 (1.2 -2.4)) and the risk of gastrointestinal diseases was highest among patients with oesophageal cancer (OR ¼ 2.0 (1.2 -3.4)).
Crude 1-year survival of cancer patients from lower SES was worse compared with the highest SES for all tumour sites combined and for the major sites separately (Table 4 ). The ageadjusted risk of death was significantly elevated for both men (HR low vs high SES ¼ 1.40, 95% CI: 1.3 -1.4) and women (HR 1.40 (1.3 -1.5)). Adding comorbidity to the model reduced HR to 1.35 Figure 2 Risk of four concomitant diseases among cancer patients with the lowest socioeconomic status (SES) compared with those with the highest SES ( ¼ reference, 1.00) according to tumour localisation with adjustment for age and gender. *95% confidence interval does not include 1.00; # No reliable estimate because o5 cases in reference category.
for men and 1.34 for women. The relative contribution of comorbidity in explaining the inequality in 1-year survival varied from 0% for lung cancer to 33% among female colorectal cancer patients.
DISCUSSION
To our knowledge, this is the first large population-based study to demonstrates the impact of SES on the prevalence of concomitant diseases among cancer patients, with increased prevalence of comorbidity in lower socioeconomic strata for each type of cancer. Cancer patients with low SES had a 50% higher risk of suffering from at least one other serious disease compared with those with high SES. The prevalence of comorbidity was significantly higher with newly diagnosed cancer of lower compared with higher SES for all 14 cancer sites studied. The diseases significantly related to SES among cancer patients were cardiovascular disease, COPD, diabetes mellitus, cerebrovascular disease, tuberculosis, diseases of the central nervous system, and gastrointestinal disease. Although both the prevalence of comorbidity and the proportional distribution of SES vary significantly among tumour types, the gradient of more comorbidity from high to low SES was apparent among all tumour types.
Smoking is probably responsible for the higher risk of cardiovascular disease, COPD, and cerebrovascular disease among low SES groups (Doll et al, 1994; Stellman and Resnicow, 1997) . This is confirmed by the higher prevalence of those diseases among patients with smoking-related tumours: cancers of the stomach, lung, bladder, and kidney (Janssen-Heijnen et al, 1998; Koppert et al, 2004) . Diabetes was more frequent among low SES for patients with cancers of the colorectum, pancreas, lung, breast, corpus uteri or prostate, or melanoma or NHL. Diabetes has been linked to pancreas cancer (Jain et al, 1991; Kalapothaki et al, 1993) either as a risk factor or as the clinical manifestation of the cancer itself (Warshaw and Fernandez-del Castillo, 1992) . Diabetes has also been associated with an increased risk for breast (Xue and Michels, 2007) , endometrial (Parazzini et al, 1991) , and colorectal cancer (Polednak, 2006) probably because of a relation with obesity (Reeves et al, 2007) . Substantial evidence exists for the association of obesity with low SES (Sobal and Stunkard, 1989; Wardle et al, 2002; McLaren, 2007) .
The prevalence of gastrointestinal diseases was highest for low SES patients with oesophageal, colorectal, lung, breast, prostate or kidney cancer, or NHL. Oesophageal cancer has also been associated with gastrointestinal diseases (Koppert et al, 2004) . A lower consumption of vegetables, fruit, and fibres, which may protect from oesophageal (Tzonou et al, 1996; Terry et al, 2001b) and colorectal cancer (Pietinen et al, 1999; Michels et al, 2000; Voorrips et al, 2000; Terry et al, 2001a; Bueno-de-Mesquita et al, 2002; Flood et al, 2002) , has been reported among lower SES (Wallstrom et al, 2000; Hulshof et al, 2003; Wardle and Steptoe, 2003) .
We used an indicator of SES based on the postal code of a residential area. This aggregate covers a very small geographical area, and thus represents a reliable approximation of individual SES. Furthermore, routinely collected income tax data (no questionnaires or interviews) have been found to provide reliable estimates of household income. Previous studies have proven that socioeconomic differences based on neighbourhood data tend to reflect such differences well at the individual level (Bos et al, 2000 (Bos et al, , 2001 Smits et al, 2001) . Furthermore, this objective measure of SES is also applicable to older women (born before 1955), whose occupation or education does not always properly reflect their social class (Berkman and Macintyre, 1997) .
Previously, we found that patients with comorbidity were often treated less aggressively, if alternative treatment strategies were available. Except for patients with a tumour with poor survival, comorbidity has an independent prognostic effect . This negative impact of comorbidity on survival of cancer might have several mechanisms: the increased risk of death due to the comorbid condition itself, more contra-indications for the cancer treatment, more indications for dose reduction and a higher rate of treatment-related complications such as infections and cardiovascular events. In several of our recent studies, the adverse effects of comorbidity on survival appeared to be independent of treatment, so less aggressive treatment could not (fully) account for the observed differences in survival between patients with and without comorbidity (Post et al, 2001; Lemmens et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005; Houterman et al, 2006) . As SES represents a combination of lifestyle, health, and risk of suboptimal treatment, cancer patients with comorbidity could also (partly) explain the poorer prognosis. Although an in-depth study remains necessary to reveal whether stage at diagnosis and treatment contributed to the SES gradient in survival, also for longer survival periods, our preliminary analyses demonstrated a clear gradient in 1-year survival rates, which could partly be attributed to comorbidity. Our study shows considerable variation in comorbidity by tumour type and a higher risk of concomitant disease among patients from lower SES. Given the aetiology of the type of tumours as well as the aetiology of the concomitant diseases that occur more frequently among patients from low SES background, a lot can probably be gained from preventive measures related to lifestyle (such as smoking and obesity). Considering survival is worse for patients of low SES, our
